Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+4.80%+3.44%+70.64%+109.32% 73.25B
-0.87%+13.19%+47.85%+88.95% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.24%+5.65%+56.71%+21.30% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+1.00%+6.52%+40.83%-13.52% 19.46B
+3.83%+2.65%+21.42%+557.58% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.36%+1.06%+55.50%+200.95% 30.79B
Weighted average by Cap. +1.76%+3.14%+54.75%+164.61%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-